CrimsoNox Capital

Overview

CrimsoNox Capital is a single-family office headquartered in Singapore, managing the assets and investments of its founding family. The firm focuses on capital preservation and long-term value creation across multiple asset classes, leveraging deep regional expertise and a disciplined approach to evaluate opportunities in both public and private markets. CrimsoNox Capital allocates capital to support sustainable growth and intergenerational wealth management. The firm's investment strategy encompasses venture capital, private equity, and hedge fund investments, targeting various stages from seed to late-stage companies. CrimsoNox Capital has a diverse geographical focus, including Singapore, the United States, India, China, and several Southeast Asian countries. The firm invests across a wide range of industries, including technology, healthcare, agriculture, 3D printing, food tech, fintech, edtech, biotech, clean energy, consumer goods, media, entertainment, logistics, e-commerce, and real estate. CrimsoNox Capital has made investments in companies such as Credo AI, Pear Therapeutics, and IVXpress. The firm has also exited investments in IVXpress and Pear Therapeutics. The firm's leadership includes CEO and Chief Investment Officer Mr. Gan Yong Aik, who co-founded CrimsoNox Capital in 2015 after a 17-year tenure at Goldman Sachs. Mr. Gan holds an MBA from Wharton and a B.A. from Nanyang Technological University, graduating with First Class Honours.

Investment Focus

• Innovative technology companies
• Sustainable growth potential
• Strong management teams
• Scalable business models
• Alignment with the firm's investment strategy

Portfolio Companies